Thinle Chodon

Medicine · Health Sciences

26h-index7.3kcitations198works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(85), Immunotherapy and Immune Responses(67), Melanoma and MAPK Pathways(54), Virus-based gene therapy research(43), Cancer Immunotherapy and Biomarkers(39)

Publications197 total

Single-Cell Mapping of TCR:Antigen Pairs Reveals Cryptic Targets in Multiple Myeloma
Transplantation and Cellular Therapy·2026
Abstract 7128: Neoantigen expression and expansion of cytotoxic T cell clonotypes in multiple myeloma patients receiving a personalized cancer vaccine post-transplant: Insights from the BM CTN 1401 multicenter trial
Cancer Research·2025
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors
Journal for ImmunoTherapy of Cancer·2025· 7 citedOpen Access
Neoantigen Expression and Expansion of Cytotoxic T Cell Clonotypes in Multiple Myeloma Patients Randomized to Post-Transplant Treatment with a Personalized Cancer Vaccine Under the BM CTN 1401 Multicenter Trial.
Transplantation and Cellular Therapy·2025
Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
Blood·2024Open Access
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
Clinical Cancer Research·2024· 2 citedOpen Access
Figure S1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
2024Open Access
Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
2024Open Access
Data from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
2024Open Access
Figure S1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
2024Open Access
Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
2024Open Access
Data from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023Open Access
Study Representativeness Table1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023Open Access
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023Open Access
Study Representativeness Table1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023Open Access
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023Open Access
P-020 Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant (HCT) results in long-term sustained T cell activation and clonotypic expansion
Clinical Lymphoma Myeloma & Leukemia·2023
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023Open Access
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023Open Access
Data from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Richard C. Koya(34), Antoni Ribas(30), Begoña Comı́n-Anduix(13), Bartosz Chmielowski(12), Begonya Comin-Anduix(11), Earl Avramis(10), Kunle Odunsi(8), Paul C. Tumeh(7), Thomas G. Graeber(7), Hubing Shi(6), Xiangju Kong(6), Roger S. Lo(6), John A. Glaspy(6), Stephen Mok(6), Junko Matsuzaki(6), Takemasa Tsuji(6), Jeffrey A. Sosman(5), Gatien Moriceau(5), Georgina V. Long(5), Charles Ng(5)